ANI Pharmaceuticals (ANIP) SVP reports tax-withholding stock dispositions

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP Chad Gassert reported tax-withholding share transactions in company stock. On February 12, 2026, 1,608 shares of common stock were disposed of at $76.70 per share as a tax-withholding disposition tied to restricted stock vesting. On February 14, 2026, a further 1,717 shares were disposed of at $77.36 per share, also to cover tax obligations on vesting restricted stock awards.

After these transactions, Gassert directly beneficially owned 66,021 shares of ANI Pharmaceuticals common stock and indirectly beneficially owned 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Gassert Chad

Role SVP - CORP. DEV. & STRATEGY

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,717	$77.36	$133K
Tax Withholding	Common Stock	1,608	$76.70	$123K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 66,021 shares (Direct); Common Stock — 158,490 shares (Indirect, Held by Chali Properties LLC)

Footnotes (1)

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,590 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,355 shares of restricted stock, the grant of which was previously reported on February 16, 2024. The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gassert Chad

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP - CORP. DEV. & STRATEGY

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		F(1)		1,608	D	$76.7	67,738	D
Common Stock	02/14/2026		F(2)		1,717	D	$77.36	66,021	D
Common Stock								158,490	I	Held by Chali Properties LLC(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,590 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,355 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

3. The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Remarks:

	/s/ Chad Gassert, by attorney-in-fact Meredith W. Cook	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ANIP executive Chad Gassert report on this Form 4?

Chad Gassert reported two tax-withholding dispositions of ANI Pharmaceuticals common stock. On February 12, 2026, 1,608 shares were disposed at $76.70, and on February 14, 2026, 1,717 shares were disposed at $77.36 to satisfy tax obligations on restricted stock vesting.

Were Chad Gassert’s ANIP Form 4 transactions open-market sales?

No, the transactions were tax-withholding dispositions, not open-market sales. The filing states the shares were withheld under Rule 16(b)-3 to cover tax liabilities arising from the vesting of previously granted restricted stock awards, rather than discretionary selling into the market.

How many ANIP shares does Chad Gassert own directly after these transactions?

Following the reported tax-withholding dispositions, Chad Gassert directly beneficially owned 66,021 shares of ANI Pharmaceuticals common stock. This figure reflects his direct holdings after the February 12, 2026 and February 14, 2026 restricted stock-related transactions disclosed in the Form 4.

What is Chali Properties LLC’s relationship to Chad Gassert in the ANIP Form 4?

The Form 4 shows 158,490 ANIP shares held indirectly through Chali Properties LLC. A footnote explains that Gassert holds voting and dispositive power over the shares held by Chali Properties LLC, so they are reported as indirect beneficial ownership.

What caused the tax-withholding share dispositions reported by ANIP’s SVP?

The tax-withholding dispositions were triggered by the vesting of restricted stock awards. Footnotes state 1,608 and 1,717 shares were withheld for taxes in connection with vesting of grants originally reported on February 18, 2025 and February 16, 2024, respectively.

What role does Chad Gassert hold at ANI Pharmaceuticals (ANIP)?

Chad Gassert is reported as an officer of ANI Pharmaceuticals with the title SVP - Corporate Development & Strategy. The Form 4 confirms he is not listed as a director or 10% owner, but as a senior executive officer of the company.